<DOC>
	<DOCNO>NCT03011424</DOCNO>
	<brief_summary>Early postoperative extracorporal liver support therapy ( ELS ) tool manage post hepatectomy liver failure ( PLF ) . Post-operative liver failure ( PLF ) identify major risk factor lead increased morbidity mortality . The incidence PLF vary largely 0-30 % , may account main reason postoperative mortality relate liver surgery ( report figure range 18 75 % ) . Currently , treatment option PLF , mainly restrict treatment complication like bile leakage , infection well prevention liver damage cause e.g . thrombosis haemorrhage well administration liver toxic drug . Recently international study group liver surgery ( ISGLS ) publish criteria new definition PLF greatly facilitate comparison result future study variety aspect liver failure . ELS use Molecular Adsorbent Recirculating System ( MARS ) base modify haemodialysis allow removal water-soluble protein bound toxins albumin-coated high flux membrane recycle exogenous albumin . Thus , MARS support compromise detoxification capacity liver well improve physiological parameter . This would offer potential temporary support harm liver liver resection allow uneventful recovery . For obvious reason previous report contain patient , present heterogonous treatment group suffer lack standardized treatment protocol . Few survive patient , thus provide evidence encourage ELS possible treatment option patient suffer PLF . However , study define patient population treatment accord predefined standardised treatment protocol warrant . Primary issue address : 1 . Can ELS apply early phase PLF ? 2 . Is ELS safe feasible treatment PLF practise accord predefined protocol ? Secondary issue address : 1 . The development predictive laboratory-chemical marker liver failure 2 . Indirect measure portal flow portal pressure 3 . Indocyanine green clearance ( ICG ) ELS treatment 4 . Clearance toxic product assess aliquot take dialysate</brief_summary>
	<brief_title>Early Postoperative Extracorporal Liver Support Therapy ( ELS ) Tool Manage Post Hepatectomy Liver Failure ( PLF )</brief_title>
	<detailed_description>Primary issue address 1 . Can ELS apply early phase PLF ? 2 . Is ELS safe feasible treatment PLF practise accord predefined protocol ? Secondary issue address 1 . The development predictive laboratory-chemical marker liver failure 2 . Indirect measure portal flow portal pressure 3 . Indocyanine green clearance ( ICG ) ELS treatment 4 . Clearance toxic product assess aliquot take dialysate Design - Prospective phase 1 safety feasibility study Study Population - 10 consecutive patient subject extend liver surgery ( least right side extend right/left side hemihepatectomy )</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Age 18 70 year Patients subject major liver surgery ( 4 Couinaud segment , ca . 50 % total liver volume ) Preoperative chemotherapy and/or biological agent allow Liver cirrhosis Child Pugh Score A allow Any contra indication ELS uncontrolled active bleeding platelet count &lt; 20.000 /Âµl Macroscopic liver cirrhosis ( Child Pugh Score B C ) Inability unwilling give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Liver resection</keyword>
	<keyword>post hepatectomy liver failure</keyword>
	<keyword>liver dialysis</keyword>
	<keyword>encephalopathy</keyword>
	<keyword>mortality</keyword>
</DOC>